Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia

(2012) D. M. Arnold et al.   BLOOD

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

(2010) F. Zaja et al.   BLOOD

Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients

(2010) Aamer Aleem et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia

(2010) Nichola Cooper et al.   Current Rheumatology Reports

Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon

(2009) Ron Ram et al.   AMERICAN JOURNAL OF HEMATOLOGY

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

(2008) Marta Medeot et al.   EUROPEAN JOURNAL OF HAEMATOLOGY